NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2031240246

Registered date:31/07/2024

Phase I/II basket trial: Boron Neutron Capture Therapy (BNCT) using CICS-1 and SPM-011 for patients with recurrent solid malignant thoracic tumors that are unresectable and perceived challenging to treat with standard treatment

Basic Information

Recruitment status Pending
Health condition(s) or Problem(s) studiedThoracic solid malignant tumor
Date of first enrollment31/07/2024
Target sample size30
Countries of recruitment
Study typeInterventional
Intervention(s)- Intravenous administration of investigational drug. 1st time/2nd time - Neutron irradiation of the clinical target volume with the investigational device. 1st time /2nd time - Intravenous injection of 18F-FBPA and radiation exposure from PET-CT scan.

Outcome(s)

Primary Outcome- Occurrence rate of dose-limiting toxicity - Response rate (RECIST v1.1)
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum>= 18age old
Age maximum<= 85age old
GenderBoth
Include criteria- Written informed consent must be obtained from the subject. - Patients with histopathological diagnosed malignant tumor (except cutaneous angiosarcoma) - Measurable disease, as defined by RECIST v1.1. - Patients diagnosed with recurrent malignant tumors that are unresectable and perceived challenging to treat with standard treatment. - Patients with ECOG performance status score of 0 or 1. - Patients whose longest diameter sum of the lesions to be treated is 15 cm or less.
Exclude criteria- Patients with active disease or active double cancers other than target lesions. - Patients with imaging findings that affect imaging evaluation of the tumor, such as ground-glass opacities - Patients who received radiation therapy exceeding 65 Gy as a prior treatment for the target lesion. - Any serious concomitant disease that precludes completion of the study treatment. - Patients with remaining complications of Grade 3 or higher related to prior radiation therapy in the irradiation field.

Related Information

Contact

Public contact
Name information Clinical trials
Address ORIX Kouraibashi Building, 3-2-7 Kouraibashi, Chuo-ku, Osaka Osaka Japan 541-0043
Telephone +81-647071516
E-mail sp-chiken@stella-pharma.co.jp
Affiliation Stella Pharma Corporation
Scientific contact
Name Toshimitsu Hayashi
Address ORIX Kouraibashi Building, 3-2-7 Kouraibashi, Chuo-ku, Osaka Osaka Japan 541-0043
Telephone +81-6-4707-1516
E-mail sp-chiken@stella-pharma.co.jp
Affiliation STELLA PHARMA CORPORATION